6. Hensgens MP, et al. All-Cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a Multicenter Cohort Study. Clin Infect Dis. 2013;56:1108-16.
7. Lowy I, et al. Treatment with Monoclonal Antibodies against Clostridium difficile Toxins. N Engl J Med. 2010;362;3:197-205.
8. Bouza E et al. Presented at 18th European Congress of Clinical Microbiology and Infectious Diseases, Barcelona 2008. Abstract0464.
9. Louie TJ, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364:422-31.
10. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med. 2008;359(18):1932−1940.
11. Cornely OA et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281-289.
12. Cornely OA et al. Resolution of Clostridium difficile-Associated Diarrhea in Patients With Cancer Treated With Fidaxomicin or Vancomycin. J Clin Onc. 2013;31(19):2493-2499.
13. Mullane KM et al. Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections. Clin Infect Dis. 2011;53(5):440-447.
14. Mullane KM et al. Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials. Am J Nephrol. 2013;38(1):1-11.
15. Loo VG et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005;353 (23):2442-2449.
16. Campbell R et al. Length of stay and hospital costs among high-risk
|SOURCE Astellas Pharma Europe Ltd |
Copyright©2012 PR Newswire.
All rights reserved